Third time’s the charm: Cere­vance’s Se­ries B ex­pands again

CNS-fo­cused Cere­vance ex­pand­ed its Se­ries B for the sec­ond time since 2020, reel­ing in an­oth­er $51 mil­lion to bankroll two Phase II clin­i­cal tri­als and one ear­ly-stage study.

The Boston biotech, which al­lied with Mer­ck last sum­mer on find­ing new Alzheimer’s drug tar­gets, said the fi­nanc­ing will fund a Phase II tri­al in Parkin­son’s dis­ease, a mid-stage study for the neg­a­tive and cog­ni­tive symp­toms of schiz­o­phre­nia and a Phase I in ALS. All are slat­ed to be­gin this year, Cere­vance said Mon­day morn­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER